Umpires first began calling both balls and strikes way back in 1864, and baseballers have been arguing about those calls ever since. Strike-zone judgment has been the subject of some untold number of ...

Let's start with CSL's leadership change, because it sets the tone. Paul McKenzie has stepped down as chief executive, and the board has appointed long-time CSL executive and current director Gordon ...

One day after CSL suddenly replaced its CEO, the company provided dismal financial figures that helped explain why. In its half-year report, CSL said its net profit plummeted (PDF) from $2 billion in ...

CSL (ASX: CSL) opened 9% lower on Wednesday to its lowest level since May 2018 after reporting a weaker-than-expected half-year result. The selloff follows a poorly timed announcement on Tuesday at ...

CSL Limited’s evolving narrative highlights how execution discipline and communication clarity can redefine market trust for even the most established healthcare leaders. Australia’s short selling ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

CSL Limited (CSL.AX) reported a significant 81% decline in net profit after tax for the first half of fiscal year 2026 due to one-off costs. The company’s revenue fell 4% to $8.3 billion, while gross ...

Despite weaker-than-expected interim numbers, CSL maintains “ambitious” full-year guidance. But investors are sceptical Rhythm Biosciences enlists its first prescriber for its Colostat bowel cancer ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The world’s largest blood plasma company is urgently seeking its own corporate transfusion after it parted ...

SYDNEY, Feb 11 (Reuters) - CSL Ltd (CSL.AX), opens new tab on Wednesday reported an 81% drop in first‑half profit, knocked by weaker blood plasma product and vaccine sales and one-off charges, a day ...

Chairman and former boss Brian McNamee has claimed the departing CEO didn’t have the skills to steer the global biotech’s future. The turmoil at the top adds to a horror six months for CSL. In that ...

CSL chair Brian McNamee (left) and new interim CEO Gordon Naylor. Supplied. In a hastily arranged analyst call on Tuesday evening, which Capital Brief attended, McNamee revealed the board had sat down ...